Charles River Laboratories International, Inc. (CRL), based in Wilmington, Massachusetts, has a market capitalization of approximately $14 billion. The company is a global contract research organization that supports pharmaceutical, biotechnology, and medical device companies. It provides research, drug discovery, safety assessment, microbial solutions, and biologics services to help develop medicines and therapies.
Companies valued between $10 billion and $200 billion are generally classified as “large-cap stocks,” and Charles River Laboratories comfortably fits this category. Its substantial market capitalization reflects its size, influence and established presence in the diagnostics and research industry. Charles River Laboratories stands at the intersection of drug discovery and development, giving it a specialized role in biomedical research. Its established reputation and diverse client base support resilient service revenue, while strategic acquisitions expand its capabilities. Strong operating cash flow also provides flexibility to invest in future growth and innovation.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Charles River Laboratories is currently 3.5% below its 52-week high of $303.30, reached on August 27, 2026. Over the past three months, CRL shares have climbed 37.7%, compared with the S&P 500’s ($SPX) 5.3% gain during the same period.
www.barchart.comCRL shares have gained 46.8% year-to-date and surged 101.2% over the past year, substantially outpacing the S&P 500’s 13.1% year-to-date gain and 17.2% return over the same time frame.
CRL has remained above both its 50-day and 200-day moving averages since late May, pointing to a sustained uptrend.
www.barchart.comCharles River Laboratories’ strong performance is supported by better-than-expected earnings and improving expectations for future profitability. On August 5, the company reported its second-quarter 2026 results, with revenue of $1 billion beating Wall Street estimates by 2.5%, while adjusted EPS of $3.02 exceeded expectations by 10.6%. Management also raised its full-year adjusted EPS guidance to $11.30 at the midpoint. The results prompted a 5.1% jump in CRL shares, suggesting the earnings beat and improved outlook strengthened investor sentiment.
Investor sentiment has received further support from the company’s longer-term growth and efficiency plans. At its September 24 Investor Day, Charles River raised its 2026 earnings outlook and projected 5% to 7% compound annual organic revenue growth through 2030, alongside an operating margin target of about 24%. Its efficiency program is also expected to generate more than $300 million in cumulative savings through 2030, potentially supporting profitability and reinforcing confidence in the company’s long-term growth prospects.
Within the competitive diagnostics and research industry, rival Thermo Fisher Scientific Inc. (TMO) has trailed CRL, with shares gaining 16.5% year-to-date and 47% over the past 52 weeks.
Wall Street analysts remain bullish on CRL’s prospects. The stock carries a consensus “Strong Buy” rating among the 16 analysts covering it. The mean price target of $307.57 implies 5% upside from current levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
HP Stock Slips as PC Maker Warns of Industry Decline in 2027 Muse Could Be the Third ‘S-Curve’ in AI So Buy Meta Platforms Stock Now How to Trade Qualcomm Stock Near Multi-Month Highs Nvidia’s CEO Expects AI-Powered Cybersecurity to Boom. These 2 Companies Are Poised to Get a Big Boost From the Trend.